[1]
|
Bertelli, R., Bonanni, A., Di, D.A., et al. (2016) Regulatory T Cells and Minimal Change Nephropathy: In the Midst of a Complex Network. Clinical & Experimental Immunology, 183, 166-174. https://doi.org/10.1111/cei.12675
|
[2]
|
Noone, D., Iijima, K. and Parekh, R. (2018) Idiopathic Nephrotic Syndrome in Children. The Lancet (London, England), 392, 61-74. https://doi.org/10.1016/S0140-6736(18)30536-1
|
[3]
|
Kamei, K., et al. (2020) Rituximab Therapy for Refractory Steroid-Resistant Nephrotic Syndrome in Children. Pediatric Nephrology, 35, 17-24. https://doi.org/10.1007/s00467-018-4166-1
|
[4]
|
Iijima, K., Sako, M., Kamei, K. and Nozu, K. (2018) Rituximab in Steroid-Sensitive Nephrotic Syndrome: Lessons from Clinical Trials. Pediatric Nephrology, 33, 1449-1455. https://doi.org/10.1007/s00467-017-3746-9
|
[5]
|
Iijima, K., Sako, M. and Nozu, K. (2017) Rituximab for Nephrotic Syndrome in Children. Clinical and Experimental Nephrology, 21, 193-202. https://doi.org/10.1007/s10157-016-1313-5
|
[6]
|
Liu, K. and Mohan, C. (2009) Altered B-Cell Signaling in Lupus. Autoimmunity Reviews, 8, 214-218.
https://doi.org/10.1016/j.autrev.2008.07.048
|
[7]
|
Chan, O.T., Hannum, L.G., Haberman, A.M., Madaio, M.P. and Shlomchik, M.J. (1999) A Novel Mouse with B Cells But Lacking Serum Antibody Reveals an Antibody-Independent Role for B Cells in Murine Lupus. Journal of Experimental Medicine, 189, 1639-1648. https://doi.org/10.1084/jem.189.10.1639
|
[8]
|
Sfi kakis, P.P., Boletis, J.N., Lionaki, S., et al. (2005) Remission of Proliferative Lupus Nephritis Following B Cell Depletion Therapy Is Preceded by Down-Regulation of the T Cell Costimulatory Molecule CD40 Ligand: An Open-Label Trial. Arthritis & Rheumatology, 52, 501-513. https://doi.org/10.1002/art.20858
|
[9]
|
Bugatti, S., Codullo, V., Caporali, R. and Montecucco, C. (2007) B Cells in Rheumatoid Arthritis. Autoimmunity Reviews, 7, 137-142. https://doi.org/10.1016/j.autrev.2007.02.017
|
[10]
|
Maloney, D.G. (2001) Mechanism of Action of Rituximab. Anticancer Drugs, 12, S1-S4.
|
[11]
|
Stasi, R., Cooper, N., Del Poeta, G., et al. (2008) Analysis of Regulatory T-Cell Changes in Patients with Idiopathic Thrombocytopenic Purpura Receiving B Cell-Depleting Therapy with Rituximab. Blood, 112, 1147-1150.
https://doi.org/10.1182/blood-2007-12-129262
|
[12]
|
Fornoni, A., Sageshima, J., Wei, C., Merscher-Gomez, S., Aguillon-Prada, R., Jauregui, A.N., et al. (2011) Rituximab Targets Podocytes in Recurrent Focal Segmental Glomerulosclerosis. Science Translational Medicine, 3, 85ra46.
https://doi.org/10.1126/scitranslmed.3002231
|
[13]
|
Takahashi, Y., Ikezumi, Y. and Saitoh, A. (2017) Rituximab Protects Podocytes and Exerts Anti-528 Proteinuric Effects in Rat Adriamycin-Induced Nephropathy Independent of B-Lymphocytes. Nephrology (Carlton), 22, 49-57.
https://doi.org/10.1111/nep.12737
|
[14]
|
Iijima, K., et al. (2014) Rituximab for Childhood-Onset, Complicated, Frequently Relapsing Nephrotic Syndrome or Steroid-Dependent Nephrotic Syndrome: A Multicentre, Double-Blind, Randomised, Placebo-Controlled Trial. The Lancet, 384, 1273-1281. https://doi.org/10.1016/S0140-6736(14)60541-9
|
[15]
|
Ruggenenti, P., et al. (2014) Rituximab in Steroid-Dependent or Frequently Relapsing Idiopathic Nephrotic Syndrome. Journal of the American Society of Nephrology, 25, 850-863. https://doi.org/10.1681/ASN.2013030251
|
[16]
|
Van Horebeek, I., et al. (2017) Rituximab in Children with Steroid-Dependent Nephrotic Syndrome: Experience of a Tertiary Center and Review of the Literature. Acta Clinica Belgica, 72, 147-155.
https://doi.org/10.1080/17843286.2016.1208955
|
[17]
|
Basu, B., et al. (2018) Efficacy of Rituximab vs Tacrolimus in Pediatric Corticosteroid-Dependent Nephrotic Syndrome. JAMA Pediatrics, 172, 757. https://doi.org/10.1001/jamapediatrics.2018.1323
|
[18]
|
Bagga, A., Moudgil, A. and Sinha, A. (2007) Rituximab in Patients with the Steroid-Resistant Nephrotic Syndrome. The New England Journal of Medicine, 356, 2751-2752. https://doi.org/10.1056/NEJMc063706
|
[19]
|
Sinha, A., et al. (2015) Efficacy and Safety of Rituximab in Children with Difficult-to-Treat Nephrotic Syndrome. Nephrology Dialysis Transplantation, 30, 96-106. https://doi.org/10.1093/ndt/gfu267
|
[20]
|
Kamei, K., et al. (2014) Rituximab Treatment Combined with Methylprednisolone Pulse Therapy and Immunosuppressants for Childhood Steroid-Resistant Nephrotic Syndrome. Pediatric Nephrology, 29, 1181-1187.
https://doi.org/10.1007/s00467-014-2765-z
|
[21]
|
Hoseini, R., et al. (2018) Efficacy and Safety of Rituximab in Children with Steroid- and Cyclosporine-Resistant and Steroid- and Cyclosporine-Dependent Nephrotic Syndrome. Iranian Journal of Kidney Diseases, 12, 27-32.
|
[22]
|
Suyama, K., et al. (2016) Rituximab and Low-Dose Cyclosporine Combination Therapy for Steroid-Resistant Focal Segmental Glomerulosclerosis. Pediatrics International, 58, 219-223. https://doi.org/10.1111/ped.12804
|
[23]
|
Prytuła, A., et al. (2010) Rituximab in Refractory Nephrotic Syndrome. Pediatric Nephrology, 25, 461-468.
https://doi.org/10.1007/s00467-009-1376-6
|
[24]
|
Sun, L., et al. (2014) Efficacy of Rituximab Therapy in Children with Refractory Nephrotic Syndrome: A Prospective Observational Study in Shanghai. World Journal of Pediatrics, 10, 59-63. https://doi.org/10.1007/s12519-014-0453-5
|
[25]
|
Bonanni, A., et al. (2018) Adverse Events Linked with the Use of Chimeric and Humanized Anti-CD20 Antibodies in Children with Idiopathic Nephrotic Syndrome. British Journal of Clinical Pharmacology, 84, 1238-1249.
https://doi.org/10.1111/bcp.13548
|
[26]
|
Parmentier, C., et al. (2020) Immunoglobulin Serum Levels in Rituximab-Treated Patients with Steroid-Dependent Nephrotic Syndrome. Pediatric Nephrology, 35, 455-462. https://doi.org/10.1007/s00467-019-04398-1
|
[27]
|
Fujinaga, S., et al. (2019) Long-Term Outcomes after Early Treatment with Rituximab for Japanese Children with Cyclosporine- and Steroid-Resistant Nephrotic Syndrome. Pediatric Nephrology, 34, 353-357.
https://doi.org/10.1007/s00467-018-4145-6
|
[28]
|
Sato, M., et al. (2013) Atypical Pneumocystis jiroveci Pneumonia with Multiple Nodular Granulomas after Rituximab for Refractory Nephrotic Syndrome. Pediatric Nephrology, 28, 145-149. https://doi.org/10.1007/s00467-012-2286-6
|
[29]
|
Ardelean, D.S., et al. (2010) Severe Ulcerative Colitis after Rituximab Therapy. Pediatrics (Evanston), 126, e243.
https://doi.org/10.1542/peds.2009-3395
|
[30]
|
Chaumais, M., et al. (2009) Fatal Pulmonary Fibrosis after Rituximab Administration. Pediatric Nephrology, 24, 1753-1755. https://doi.org/10.1007/s00467-009-1195-9
|
[31]
|
Grenda, R., Jarmużek, W., Rubik, J., Migdał, M. and Pronicki, M. (2015) Fatal Rituximab-Associated Lung Injury Syndrome in a Patient Treated with Rituximab for Recurrence of Post-Transplant Nephrotic Syndrome. Pediatric Transplantation, 19, E115-E120. https://doi.org/10.1111/petr.12481
|